CUT 350 / Unit: 10 x 1 ml Amps(250 mg/ml)

CUT 350 - Unit: 10 x 1 ml Amps(250 mg/ml)

1 Reviews
REF-IS-BT-CUT2-10
In-stock
$84.00
No tax

Active Ingredient: Mix

Trenbolone Acetate USP 100 mg

Drostanolone Propionate 75 mg

Methenolone Enanthate 75 mg

Testosterone Propionate 100mg

Pack: 10 x 1 ml Amps(350 mg/ml)

Manufacturer: Biotech

Half Life: 7 days

Detection Time: up to 8 months

Anabolic Rating: N/A

Androgenic Rating: N/A

Dosage: male 250-500 mg per week, female 100 mg per week.

CUT 350® is a very steroid potent formula an oil based solution mix of 4 compounds: Trenbolone Acetate, Drostanolone Propionate and Methenolone Enanthate for intramuscular injection that producing an anabolic effect and promoting protein synthesis as well as creating positive nitrogen balance in humans. Trenbolone increases protein and decreases fat deposition. It has proven to be an excellent product for promoting size and strength in the presence of adequate protein and calories, promotes body tissue building processes, and can reverse catabolism. High doses of Methenolone Enanthate may stimulate bone marrow function, particularly erythropoiesis.

CLINICAL PHARMACOLOGY:

CUT 350® is a fast-acting injectable steroid compound with a great effect on protein metabolism. Trenbolone is one of the best effective anabolic compounds, promoting protein synthesis, as well as creating a positive nitrogen balance. Methenolone Enanthate is an appetite stimulant and improves the conversion of proteins.In aplastic anemias of various origins - both the idiopathic forms and those with exogenously damaged bone marrow - high doses of CUT 350® may stimulate bone marrow function, particularly erythropoiesis. Anabolic steroids suppress the gonadotropic functions of the pituitary and may exert a direct effect upon the testes. During exogenous administration of anabolic androgens, endogenous testosterone release is inhibited through inhibition of pituitary luteinizing hormone (LH). At large doses, spermatogenesis may be suppressed through feedback inhibition of pituitary follicle- stimulating hormone (FSH).Drostanolone attaches to androgen receptors; increasing nitrogen retention and protein synthesis. Drostanolone acts on dihydrotestosterone modulated pathways as well.Drostanolone is a potent estrogen antagonist and does not aromatize to estrogen, limiting expression of side effects often linked to estrogen such as water retention, gynecomastia, and some types of high blood pressure. Drostanolone undergoes hepatic metabolism with a half- life of 2-3 days after separation of the ester. During exogenous administration of androgens, endogenous testosterone release is inhibited through feedback inhibition of pituitary luteinizing hormone (LH). At large doses of exogenous androgens, spermatogenesis may also be suppressed through feedback inhibition of pituitary follicle stimulating hormone (FSH).Testosterone propionate is less polar than free testosterone. Propionate is less polar than free testosterone. TESTO 100® in oil injected intramuscularly is absorbed slowly from the lipid phase; thus, it can be given at intervals of 2 to 3times/week. Testosterone in plasma is 98% bound to a specific testosterone estradiol binding globulin, and about 2% is free. Generally, the amount of this sex-hormone binding globulin in the plasma will determine the distribution of testosterone between free and bound forms, and the free testosterone concentration will determine half-life.

INDICATIONS AND USAGE:

1.Aplastic anemias. The therapy may have to be continued for at least 3 months at a dosage of 200-300 mg per week. Since some patients only respond after several months, treatment must not be stopped too soon. After improvement of the clinical picture treatment should, as a general rule, be continued for a further few weeks. Deterioration of the blood count after discontinuation of therapy may be reversed by renewed administration of CUT 350®

2.Osteoporosis.

3.Progressive breast cancer

CONTRAINDICATIONS:

1.Not indicated for women, children, or the elderly.

2.Women who are pregnant or may become pregnant because of possible masculinization of the fetus.

3.Patients with nephrosis or the nephrotic phase of nephritis.

4.Patients with hypercalcemia.

5.Patients suffering from testicular cancer, prostate cancer, breast cancer, liver damage, kidney damage, stroke, high blood pressure, heart disease or respiratory problems.

6.Because of this androgenic activity, CUT 350® Injection is also contra-indicated in patients with prostatic carcinoma, since such substances may aggravate the disease.

7.CUT 350® is a androgenic hormone and as to be expected there are possible androgenic side effects.Such effects include acne, accelerated hair loss in those predisposed to male pattern baldness, and body hair growth. While such effects are possible they are entirely dependent on your genetics.

WARNINGS:

SIDE EFFECTS AND SPECIAL PRECAUTIONS:

Side effects with CUT 350® are minimal and manifest themselves only rarely and in persons who are extremely sensitive. Due to the androgenic residual effect, side effects include light acne, deep voice or increased hair growth. CUT 350® has even less influence on the liver function than the oral form so that an increase of the liver toxicity values is extremely unlikely. The blood pressure, cholesterol level, HDL and LDL values, as with CUT 350® tablets, usually remain unaffected. CUT 350® is generally the safest injectable steroid.

In female patients, signs of virilisation (acne, hirsutism, hoarseness, possibly irreversible deepening of the voice) must be reckoned with; in sexually mature women menstrual irregularities may occur.

In adult males, spermatogenesis may be inhibited, in boys there may be signs of premature puberty.

Non-adult patients should be monitored for accelerated bone maturation by X-ray. Impairment of liver function is less frequent than with a 17alpha-alkylated anabolic steroid.

In men, regular examinations of the prostate should be carried out prophylactically to exclude a malignant tumour.

ADVERSE REACTIONS:

The following adverse reactions in the male have occurred with some androgens:

Endocrine and urogenital: Gynecomastia and excessive frequency and duration of penile erection. Oligospermia may occur at high dosages.

Skin and appendages: Hirsutism, male pattern of baldness, seborrhea, and acne.

Fluid and electrolyte disturbances: Retention of sodium, chloride, water, potassium, calcium, and inorganic phosphates.

Gastrointestinal: Nausea, cholestatic jaundice, alterations in liver function tests, rarely hepatocellular neoplasms and peliosis hepatic (see WARNINGS).

Hematologic: Suppression of clotting factors II, V, VII, and X, bleeding in patients on concomitant anticoagulant therapy, and polycythemia.

Nervous system: Increased or decreased libido, headache, anxiety, depression, and generalized paresthesia.

Allergic: Hypersensitivity, including skin manifestations and anaphylactic reactions. Miscellaneous: Inflammation and pain at the site of intramuscular injection.

CUT 350® can have a strong, negative impact on cholesterol by suppressing HDL cholesterol (good cholesterol) and increasing LDL cholesterol (bad cholesterol). This negative effect on cholesterol should not be as strong as most oral anabolic steroids, but it will be far more pronounced than most injectable steroids. It is controllable, but it will take a concentrated effort. A cholesterol friendly lifestyle is imperative, which means a cholesterol friendly diet rich in omega fatty acids, low in saturated fats, and low in simple sugars. It also means incorporating regular cardiovascular activity into your routine, even during off-season periods of growth.

LIVER CELL TUMORS ARE REPORTED. MOST OFTEN THESE TUMORS ARE BENIGN AND ANDROGEN DEPENDENT, BUT FATAL MALIGNANT TUMORS HAVE BEEN REPORTED. WITH DRAWAL OF DRUG OFTEN RESULTS IN REGRESSION OR CESSATION OF PROGRESSION OF THE TUMOR. HOWEVER, HEPATIC TUMORS ASSOCIATED WITH ANDROGENS OR ANABOLIC STEROIDS ARE MUCH MORE VASCULAR THAN OTHER HEPATIC TUMORS AND MAY BE SILENT UNTIL LIFE-THREATENING INTRA-ABDOMINAL HEMORRHAGE DEVELOPS.

PELIOSIS HEPATIS, A CONDITION ARE ALSO REPORTED IN WHICH LIVER AND SOMETIMES SPLENIC TISSUE IS REPLACED WITH BLOOD-FILLED CYSTS, HAS BEEN REPORTED IN PATIENTS RECEVING ANDROGENIC ANABOLIC STEROID THERAPY. THESE CYSTS ARE SOMETIMES PRESENT WITH MINIMAL HEPATIC DYSFUNCTION, BUT AT OTHER TIMES THEY HAVE BEEN ASSOCIATED WITH LIVER FAILURE. THEY ARE OFTEN NOT RECOGNIZED UNTIL LIFE-THREATENING LIVER FAILURE OR INTRA-ABDOMINAL HEMORRHAGE DEVELOPS. WITHDRAWAL OF DRUG USUALLY RESULTS IN COMPLETE DISAPPERRANCE OF LESIONS.

BLOOD LIPID CHANGES THAT ARE KNOWN TO BE ASSOCIATED WITH INCREASED RISK OF ATHEROSCLEROSIS ARE SEEN IN PATIENTS TREATED WITH ANDROGENS AND ANABOLIC STEROIDS. THESE CHANGES INCLUDE DECREASED HIGH-DENSITY LIPOPROTEIN AND SOMETIMES INCREASED LOW-DENSITY LIPOPROTEIN. THE CHANGES MAY BE VERY MARKED AND COULD HAVE A SERIOUS IMPACT ON THE RISK OF ATHEROSCLEROSIS AND CORONARY ARTERY DISEASE.

OVERDOSAGE:

There have been no reports of acute overdosage with the androgens.

DOSAGE AND ADMINISTRATION:

CUT 350® is for intramuscular use only. It should not be given intravenously. Intramuscular injections should be given deep in the gluteal muscle

Aplastic anemia: The therapy may have to be continued for at least 3 months at a dosage of 200-300 mg per week.

Osteoporosis: The suggested dosage is 125 mg every 2 weeks, reducing to once every 3 to 4 weeks after an initial response.

Body Building: effectively injection dose: male 250-500 mg per week and female 100 mg per week.

Special comment: Women normally prefer the 25 mg tablets but there are several female athletes who inject 100-200 mg or more CUT 350® per week. 100 mg CUT 350® per week, combined with 50 mg Stanozolol per week, is usually an effective stack for many women and is tolerated well so that virilization symptoms are rarely observed. To avoid an undesired accumulation of androgens in the body women should pay attention that there are three to four days in between the relative injections. For competing female athletes this stack, however, is too weak. CUT 350® is often used in a dose of 100 mg per week to bridge over steroid breaks which, in our opinion, is not a good idea: The non-stop use of anabolic steroids has a strong negative influence on the body's own testosterone production and prevents the body from normalizing its functions. Dosages as low as 100 mg CUT 350® per week (also often used for bridging) are nontoxic and mostly have no side effects. However, the effectiveness of such an intake must be strongly doubted since both compounds in this dosage are much too weak in order to effectively counter affect the catabolic phase, which begins in the steroid phases. Better results can usually be obtained with Clenbuterol without influencing the hormone system. Those who believe that in the "steroid free time" they must still take some "stuff' to bridge the usages should inject the long acting Testosterone Enanthate(e.g. Testoviron® 250 mg per ml) every two to three weeks.

1.HOW SUPPLIED - CUT 350®

injection, solution- Intramuscular-350 mg/ml is supplied in 1 ml ampoule of 10 ampoule pack.

For shelf-life please refer to the imprint on the pack.

Keep out of reach of children.

Should be at controlled room temperatures 15-30°C (59-86°F)

Do not freeze

This drug should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Warming and shaking the vial should redissolve any crystals that may have formed during storage at temperatures lower than recommended.

Protect from sun light

This drug has not been shown to be safe and effective for the enhancement of athletic performance!

1 Reviews

OK
Happy with results, will order more soon.
on

Customers who bought this product also bought:

Product added to wishlist
Product added to compare.